Take action again! WUXI APPTEC sells 7.17% of WUXI XDC Stocks | Quick read of the announcement.

① The Stocks sold by WUXI APPTEC account for about 7.17% of the current total share capital of WUXI XDC, with a cumulative transaction amount of approximately 2.426 billion Hong Kong dollars; ② This is the second time WUXI APPTEC has recently sold related Assets; ③ WUXI XDC's revenue for the first half of 2024 increased by 67.6% year-on-year.

cls.cnJan 13 08:35 ET

This week, an additional 29 companies have announced! TIGERMED and several other stocks disclosed repurchase and shareholding refinancing plans, with a list of related A-shares overview.

① The number of A-share listed companies receiving special loan support continues to expand. According to incomplete Statistics, as of the time of writing, 29 listed companies have disclosed information related to share repurchase and increased shareholding for re-loan this week (see attached table); ② TIGERMED received the highest amount of special loan support, totaling no more than 0.7 billion yuan.

cls.cnJan 11 03:22 ET

An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.

① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.

cls.cnJan 9 08:38 ET

Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges

BenzingaJan 8 08:17 ET

WUXI BIO sells overseas Assets, but not because of the biosecurity legislation.

By adjusting the Assets, WUXI BIO has released more space and will further increase its overseas investments.

wallstreetcnJan 7 03:07 ET

WUXI BIO has once again divested overseas Assets! Merck takes over WUXI BIO's Ireland vaccine factory for 0.5 billion USD | Quick read announcement.

① WUXI BIO announced today that it will sell the Ireland vaccine factory to Merck for 0.5 billion USD; ② this vaccine factory was originally built to undertake Merck's vaccine contract manufacturing business; ③ not long ago, WUXI APPTEC also divested its WuXi ATU business in the USA and United Kingdom.

cls.cnJan 6 09:47 ET